You are here
Home- Overview
- Keynote Speakers
- Sponsors
- Agenda
- Location
- 8:30 AM to 5:00 PM
- Vantage Venues vantagevenues.com 150 King St West, Toronto ON M5H 1J9
The UHN Lung Oncology Site Group is excited to announce its 5th annual Lung Oncology Research Day, to be held in person on Friday, October 25, 2024. This year’s theme will be Impact of AI in Pathology and Radiology.
This annual event celebrates our achievements in clinical and translational research and is an opportunity to promote interdepartmental collaborations amount researchers. The purpose of this conference is for the lung group to share, update, and discuss ongoing lung cancer research across the entire multi-disciplinary spectrum with participation from researchers, clinicians, and trainees.
Trainees (i.e., clinical fellows, postdoctoral fellows,& residents) currently working under the supervision of a Principal Investigator at the lung site are invited to submit an abstract for an oral presentation.
Abstracts submitted to international or national meetings over the past year are welcome. There will be Awards for the best clinical and basic science presentations.
Registration is free and we encourage everyone to register as soon as possible.
If you plan to submit an abstract, please register and then email your abstract to lungoncologygroup@uhn.ca
Please mark your calendars for October 25, 2024 and we look forward to seeing you there!
IMPORTANT DATES:
Abstract Submission Deadline: Thursday, October 10, 2024 at 4:00 p.m. (no late submissions will be accepted)
Registration Closes: Sunday, October 20, 2024 at 4:00 pm.
Online registration is mandatory for all presenters and general attendees.
Dr. Ignacio I. Wistuba, MD
Professor and Chair, Department of Translational Molecular Pathology, Division of Pathology/Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Dr. Ignacio Wistuba is the Chair of the Department of Translational Molecular Pathology and Professor of the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.
Dr. Wistuba’s research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer. Dr. Wistuba's work includes the identification of new molecular targets, validation of biomarkers for targeted therapy, and identification of molecular markers associated with metastasis development.
Dr. Pamela Ohashi, PhD, FRSC
Dr. Ohashi received her Ph.D from the University of Toronto with Dr. Tak Mak, and did her post-doctoral training at the University of Zurich with the Nobel Laureate Dr. Zinkernagel, and Dr. Hans Hengartner. She is a Senior Scientist and Director of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre, and a Professor in the Department of Immunology at the University of Toronto. Her interests include understanding CD8+ T cell biology and mechanisms that regulate anti-tumor immunity.
Dr. Daniel De Carvalho, PhD
Dr. Daniel De Carvalho is a Senior Scientist at the Princess Margaret Cancer Centre and Assistant Professor in the Department of Medical Biophysics at the University of Toronto. Dr. De Carvalho's research focuses on basic and translational aspects of cancer epigenetics. His lab is developing DNA methylation-based liquid biopsy tools combined with advanced computational approaches applied to cancer early detection, classification and monitoring.
Dr. Patrick Veit-Haibach, MD
Dr. Patrick Veit-Haibach is a dual-certified Radiologist and Nuclear Medicine Physician. He is the Director of the PET/MR program in the Joint Department of Medical Imaging and Professor of Radiology & Nuclear Medicine in the Department of Medical Imaging at the University of Toronto.
His research interests focus on multi-modality molecular imaging strategies, particularly combined PET/MRI and PET/CT, perfusion- and hypoxia-imaging. Current projects involve clinical and preclinical molecular imaging research in esophago-gastric cancer, hematological and lymphomatous malignancies, breast cancer, HCC, sarcoma and ENT cancer as well as hybrid-modality hypoxia imaging and machine learning endeavors in PET.
Dr. Farzad Khalvati, M.A.Sc., PhD
Dr. Farzad Khalvati is a Senior Scientist and Endowed Chair in Medical Imaging and Artificial Intelligence and Director of the Intelligent Medical Informatics Computing Systems (IMICS) Lab at The Hospital for Sick Children. He is an Associate Professor in the Department of Medical Imaging and Institute of Medical Science.
Dr. Khalvati leads the design, development, validation, and deployment of AI tools for medicine using multi-modal data such as medical imaging and healthcare informatics.
GOLD SPONSORS
SILVER SPONSORS
BRONZE SPONSORS
TBA